A new AI-based imaging solution for children with suspected tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the feasibility of using deep learning-assisted rapid silent PET/MR imaging specifically for pediatric patients. It aims to overcome the challenges of traditional PET/MR imaging by incorporating flexible coils and silent sequences to enhance comfort and reduce the radiation dose. The goal is to provide a quick and effective imaging solution for children suspected of having malignant tumors, ensuring a more pleasant experience during the examination.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Children who have clinical symptoms and are suspected of having malignant tumors after being evaluated by clinical pediatricians and require 18F-FDG PET/MR examination to further clarify their conditions.
2. Signed and dated informed consent form
3. Commit to complying with the research procedures and cooperate in the implementation of the entire research process.
4. No gender restriction, aged between 0 and 18 years old.

Exclusion Criteria:

1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
2. Patients with severe claustrophobia，epileptic seizures, respiratory distress who cannot lie down, and patients with mental anomalies who are unable to cooperate.
3. Patients with metal implants such as pacemakers, artificial metal heart valves, and neurostimulators in their bodies.
4. Non-compliant person.

Where it's running

• China, Shanghai Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Jiajia Hu
• Email: jiajiahu@shsmu.edu.cn
• Phone: 13524945287

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-assisted 4D PET imaging to detect early pancreatic cancer lesions

  This study tests whether AI-assisted 4D long-axial PET imaging with FDG and FAPI can help detect early PDAC lesions in patients with suspected pancreatic tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07925125

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• Neoadjuvant therapy for locally advanced low rectal cancer: adding fruquintinib to short-course radiotherapy with tislelizumab and CAPOX

  This study tests whether adding fruquintinib to short-course radiotherapy plus tislelizumab and CAPOX before surgery helps people with locally advanced low rectal cancer achieve a better tumor response.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07888309

• Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer

  This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07888140

• Ivonescimab with pemetrexed and platinum chemotherapy as first-line treatment for advanced malignant pleural mesothelioma

  This study tests whether adding ivonescimab to standard pemetrexed plus platinum-based chemotherapy can help people with newly diagnosed advanced malignant pleural mesothelioma.

  Recruiting at 3 sites Phase 1/2 Ruijin Hospital · Shanghai, Shanghai Municipality and 2 other locations · NCT07885319

• Gecacitinib for patients with myeloid neoplasms and myelofibrosis undergoing allogeneic stem cell transplant

  This study tests whether taking gecacitinib around the time of allogeneic stem cell transplantation is safe and helps engraftment in adults with myeloid neoplasms and myelofibrosis.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai · NCT07883382

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.